US 10,376,455 B2
Biophotonic compositions and methods for providing biophotonic treatment
Remigio Piergallini, Grottammare Ascoli Piceno (IT); Nikolaos Loupis, Athens (GR); and Shipra Rastogi, Montreal (CA)
Assigned to KLOX TECHNOLOGIES INC., Laval, Quebec (CA)
Filed by KLOX Technologies Inc., Laval (CA)
Filed on Jul. 1, 2016, as Appl. No. 15/201,111.
Application 15/201,111 is a continuation of application No. 13/830,488, filed on Mar. 14, 2013, abandoned.
Claims priority of provisional application 61/766,611, filed on Feb. 19, 2013.
Claims priority of provisional application 61/701,502, filed on Sep. 14, 2012.
Claims priority of provisional application 61/701,510, filed on Sep. 14, 2012.
Claims priority of provisional application 61/701,513, filed on Sep. 14, 2012.
Claims priority of provisional application 61/636,480, filed on Apr. 20, 2012.
Claims priority of provisional application 61/636,574, filed on Apr. 20, 2012.
Claims priority of provisional application 61/636,577, filed on Apr. 20, 2012.
Prior Publication US 2017/0027833 A1, Feb. 2, 2017
Int. Cl. A61K 8/04 (2006.01); A61K 8/22 (2006.01); A61K 8/49 (2006.01); A61N 5/06 (2006.01); A61Q 19/00 (2006.01); A61K 8/81 (2006.01); A61K 41/00 (2006.01); A61Q 19/02 (2006.01); A61Q 19/08 (2006.01)
CPC A61K 8/498 (2013.01) [A61K 8/042 (2013.01); A61K 8/22 (2013.01); A61K 8/8147 (2013.01); A61K 41/00 (2013.01); A61K 41/0057 (2013.01); A61N 5/06 (2013.01); A61N 5/062 (2013.01); A61N 5/0616 (2013.01); A61Q 19/00 (2013.01); A61Q 19/02 (2013.01); A61Q 19/08 (2013.01); A61K 2800/262 (2013.01); A61K 2800/434 (2013.01); A61K 2800/5922 (2013.01); A61K 2800/81 (2013.01); A61N 2005/0645 (2013.01); A61N 2005/0647 (2013.01); A61N 2005/0662 (2013.01); A61N 2005/0663 (2013.01)] 22 Claims
 
1. A method for reducing scarring formation, comprising:
topically applying a biophotonic composition to a scarred tissue, comprising a chromophore and a gelling agent; wherein the biophotonic composition is substantially translucent having a transmission of light of more than 20% and has a viscosity of between about 15 000 cP and about 100 000 cP; and
illuminating said biophotonic composition with actinic light, wherein the actinic light delivers a power density of less than about 150 mW/cm2 when located at 5 cm from the scarred tissue and wherein the biophotonic composition is activatable upon being illuminated with the actinic light for a period between about 1 second and about 30 seconds;
wherein the gelling agent renders the biophotonic composition substantially resistant to leaching such that less than 15% of a total amount of the chromophore leaches out of the biophotonic composition into tissue during treatment.